Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocol.
BACKGROUND: Kidney transplantation is the best treatment for patients with end-stage renal failure, but uncertainty remains about the best immunosuppression strategy. Long-term graft survival has not improved substantially, and one possible explanation is calcineurin inhibitor (CNI) nephrotoxicity....
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2013
|
| _version_ | 1826303839363399680 |
|---|---|
| author | Haynes, R Baigent, C Harden, P Landray, M Akyol, M Asderakis, A Baxter, A Bhandari, S Chowdhury, P Clancy, M Emberson, J Gibbs, P Hammad, A Herrington, W Jayne, K Jones, G Krishnan, N Lay, M Lewis, D Macdougall, I Nathan, C Neuberger, J Newstead, C Pararajasingam, R Puliatti, C |
| author_facet | Haynes, R Baigent, C Harden, P Landray, M Akyol, M Asderakis, A Baxter, A Bhandari, S Chowdhury, P Clancy, M Emberson, J Gibbs, P Hammad, A Herrington, W Jayne, K Jones, G Krishnan, N Lay, M Lewis, D Macdougall, I Nathan, C Neuberger, J Newstead, C Pararajasingam, R Puliatti, C |
| author_sort | Haynes, R |
| collection | OXFORD |
| description | BACKGROUND: Kidney transplantation is the best treatment for patients with end-stage renal failure, but uncertainty remains about the best immunosuppression strategy. Long-term graft survival has not improved substantially, and one possible explanation is calcineurin inhibitor (CNI) nephrotoxicity. CNI exposure could be minimized by using more potent induction therapy or alternative maintenance therapy to remove CNIs completely. However, the safety and efficacy of such strategies are unknown. METHODS/DESIGN: The Campath, Calcineurin inhibitor reduction and Chronic allograft nephropathy (3C) Study is a multicentre, open-label, randomized controlled trial with 852 participants which is addressing two important questions in kidney transplantation. The first question is whether a Campath (alemtuzumab)-based induction therapy strategy is superior to basiliximab-based therapy, and the second is whether, from 6 months after transplantation, a sirolimus-based maintenance therapy strategy is superior to tacrolimus-based therapy. Recruitment is complete, and follow-up will continue for around 5 years post-transplant. The primary endpoint for the induction therapy comparison is biopsy-proven acute rejection by 6 months, and the primary endpoint for the maintenance therapy comparison is change in estimated glomerular filtration rate from baseline to 2 years after transplantation. The study is sponsored by the University of Oxford and endorsed by the British Transplantation Society, and 18 centers for adult kidney transplant are participating. DISCUSSION: Late graft failure is a major issue for kidney-transplant recipients. If our hypothesis that minimizing CNI exposure with Campath-based induction therapy and/or an elective conversion to sirolimus-based maintenance therapy can improve long-term graft function and survival is correct, then patients should experience better graft function for longer. A positive outcome could change clinical practice in kidney transplantation. TRIAL REGISTRATION: ClinicalTrials.gov, NCT01120028 and ISRCTN88894088. |
| first_indexed | 2024-03-07T06:08:48Z |
| format | Journal article |
| id | oxford-uuid:eec08621-622b-46a7-a3ee-b4169ef4281c |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T06:08:48Z |
| publishDate | 2013 |
| record_format | dspace |
| spelling | oxford-uuid:eec08621-622b-46a7-a3ee-b4169ef4281c2022-03-27T11:35:17ZCampath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocol.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:eec08621-622b-46a7-a3ee-b4169ef4281cEnglishSymplectic Elements at Oxford2013Haynes, RBaigent, CHarden, PLandray, MAkyol, MAsderakis, ABaxter, ABhandari, SChowdhury, PClancy, MEmberson, JGibbs, PHammad, AHerrington, WJayne, KJones, GKrishnan, NLay, MLewis, DMacdougall, INathan, CNeuberger, JNewstead, CPararajasingam, RPuliatti, CBACKGROUND: Kidney transplantation is the best treatment for patients with end-stage renal failure, but uncertainty remains about the best immunosuppression strategy. Long-term graft survival has not improved substantially, and one possible explanation is calcineurin inhibitor (CNI) nephrotoxicity. CNI exposure could be minimized by using more potent induction therapy or alternative maintenance therapy to remove CNIs completely. However, the safety and efficacy of such strategies are unknown. METHODS/DESIGN: The Campath, Calcineurin inhibitor reduction and Chronic allograft nephropathy (3C) Study is a multicentre, open-label, randomized controlled trial with 852 participants which is addressing two important questions in kidney transplantation. The first question is whether a Campath (alemtuzumab)-based induction therapy strategy is superior to basiliximab-based therapy, and the second is whether, from 6 months after transplantation, a sirolimus-based maintenance therapy strategy is superior to tacrolimus-based therapy. Recruitment is complete, and follow-up will continue for around 5 years post-transplant. The primary endpoint for the induction therapy comparison is biopsy-proven acute rejection by 6 months, and the primary endpoint for the maintenance therapy comparison is change in estimated glomerular filtration rate from baseline to 2 years after transplantation. The study is sponsored by the University of Oxford and endorsed by the British Transplantation Society, and 18 centers for adult kidney transplant are participating. DISCUSSION: Late graft failure is a major issue for kidney-transplant recipients. If our hypothesis that minimizing CNI exposure with Campath-based induction therapy and/or an elective conversion to sirolimus-based maintenance therapy can improve long-term graft function and survival is correct, then patients should experience better graft function for longer. A positive outcome could change clinical practice in kidney transplantation. TRIAL REGISTRATION: ClinicalTrials.gov, NCT01120028 and ISRCTN88894088. |
| spellingShingle | Haynes, R Baigent, C Harden, P Landray, M Akyol, M Asderakis, A Baxter, A Bhandari, S Chowdhury, P Clancy, M Emberson, J Gibbs, P Hammad, A Herrington, W Jayne, K Jones, G Krishnan, N Lay, M Lewis, D Macdougall, I Nathan, C Neuberger, J Newstead, C Pararajasingam, R Puliatti, C Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocol. |
| title | Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocol. |
| title_full | Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocol. |
| title_fullStr | Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocol. |
| title_full_unstemmed | Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocol. |
| title_short | Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocol. |
| title_sort | campath calcineurin inhibitor reduction and chronic allograft nephropathy 3c study background rationale and study protocol |
| work_keys_str_mv | AT haynesr campathcalcineurininhibitorreductionandchronicallograftnephropathy3cstudybackgroundrationaleandstudyprotocol AT baigentc campathcalcineurininhibitorreductionandchronicallograftnephropathy3cstudybackgroundrationaleandstudyprotocol AT hardenp campathcalcineurininhibitorreductionandchronicallograftnephropathy3cstudybackgroundrationaleandstudyprotocol AT landraym campathcalcineurininhibitorreductionandchronicallograftnephropathy3cstudybackgroundrationaleandstudyprotocol AT akyolm campathcalcineurininhibitorreductionandchronicallograftnephropathy3cstudybackgroundrationaleandstudyprotocol AT asderakisa campathcalcineurininhibitorreductionandchronicallograftnephropathy3cstudybackgroundrationaleandstudyprotocol AT baxtera campathcalcineurininhibitorreductionandchronicallograftnephropathy3cstudybackgroundrationaleandstudyprotocol AT bhandaris campathcalcineurininhibitorreductionandchronicallograftnephropathy3cstudybackgroundrationaleandstudyprotocol AT chowdhuryp campathcalcineurininhibitorreductionandchronicallograftnephropathy3cstudybackgroundrationaleandstudyprotocol AT clancym campathcalcineurininhibitorreductionandchronicallograftnephropathy3cstudybackgroundrationaleandstudyprotocol AT embersonj campathcalcineurininhibitorreductionandchronicallograftnephropathy3cstudybackgroundrationaleandstudyprotocol AT gibbsp campathcalcineurininhibitorreductionandchronicallograftnephropathy3cstudybackgroundrationaleandstudyprotocol AT hammada campathcalcineurininhibitorreductionandchronicallograftnephropathy3cstudybackgroundrationaleandstudyprotocol AT herringtonw campathcalcineurininhibitorreductionandchronicallograftnephropathy3cstudybackgroundrationaleandstudyprotocol AT jaynek campathcalcineurininhibitorreductionandchronicallograftnephropathy3cstudybackgroundrationaleandstudyprotocol AT jonesg campathcalcineurininhibitorreductionandchronicallograftnephropathy3cstudybackgroundrationaleandstudyprotocol AT krishnann campathcalcineurininhibitorreductionandchronicallograftnephropathy3cstudybackgroundrationaleandstudyprotocol AT laym campathcalcineurininhibitorreductionandchronicallograftnephropathy3cstudybackgroundrationaleandstudyprotocol AT lewisd campathcalcineurininhibitorreductionandchronicallograftnephropathy3cstudybackgroundrationaleandstudyprotocol AT macdougalli campathcalcineurininhibitorreductionandchronicallograftnephropathy3cstudybackgroundrationaleandstudyprotocol AT nathanc campathcalcineurininhibitorreductionandchronicallograftnephropathy3cstudybackgroundrationaleandstudyprotocol AT neubergerj campathcalcineurininhibitorreductionandchronicallograftnephropathy3cstudybackgroundrationaleandstudyprotocol AT newsteadc campathcalcineurininhibitorreductionandchronicallograftnephropathy3cstudybackgroundrationaleandstudyprotocol AT pararajasingamr campathcalcineurininhibitorreductionandchronicallograftnephropathy3cstudybackgroundrationaleandstudyprotocol AT puliattic campathcalcineurininhibitorreductionandchronicallograftnephropathy3cstudybackgroundrationaleandstudyprotocol |